Literature DB >> 19564641

CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice.

Silvia Bijland1, Sjoerd A A van den Berg, Peter J Voshol, Anita M van den Hoek, Hans M G Princen, Louis M Havekes, Patrick C N Rensen, Ko Willems van Dijk.   

Abstract

The cholesteryl ester transfer protein (CETP) facilitates the bidirectional transfer of cholesteryl esters and triglycerides (TG) between HDL and (V)LDL. By shifting cholesterol in plasma from HDL to (V)LDL in exchange for VLDL-TG, CETP aggravates atherosclerosis in hyperlipidemic APOE*3-Leiden (E3L) mice. The aim of this study was to investigate the role of CETP in TG metabolism and high-fat diet-induced obesity by using E3L mice with and without the expression of the human CETP gene. On chow, plasma lipid levels were comparable between both male and female E3L and E3L.CETP mice. Further mechanistic studies were performed using male mice. CETP expression increased the level of TG in HDL. CETP did not affect the postprandial plasma TG response or the hepatic VLDL-TG and VLDL-apolipoprotein B production rate. Moreover, CETP did not affect the plasma TG clearance rate or organ-specific TG uptake after infusion of VLDL-like emulsion particles. In line with the absence of an effect of CETP on tissue-specific TG uptake, CETP also did not affect weight gain in response to a high-fat diet. In conclusion, the CETP-induced increase of TG in the HDL fraction of E3L mice is not associated with changes in the production of TG or with tissue-specific clearance of TG from the plasma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19564641      PMCID: PMC2789790          DOI: 10.1194/jlr.M900186-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  29 in total

Review 1.  JTT-705: is there still future for a CETP inhibitor after torcetrapib?

Authors:  Alexander J M Rennings; Anton F H Stalenhoef
Journal:  Expert Opin Investig Drugs       Date:  2008-10       Impact factor: 6.206

2.  Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation.

Authors:  Shirya Rashid; P Hugh R Barrett; Kristine D Uffelman; Takehiko Watanabe; Khosrow Adeli; Gary F Lewis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-03-01       Impact factor: 8.311

Review 3.  High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.

Authors:  W E Boden
Journal:  Am J Cardiol       Date:  2000-12-21       Impact factor: 2.778

4.  Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.

Authors:  Greetje J de Grooth; Jan Albert Kuivenhoven; Anton F H Stalenhoef; Jacqueline de Graaf; Aeilko H Zwinderman; Jan L Posma; Arie van Tol; John J P Kastelein
Journal:  Circulation       Date:  2002-05-07       Impact factor: 29.690

5.  ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance.

Authors:  J C Escolà-Gil; J Julve; A Marzal-Casacuberta ; J Ordóñez-Llanos; F González-Sastre; F Blanco-Vaca
Journal:  J Lipid Res       Date:  2001-02       Impact factor: 5.922

6.  Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis.

Authors:  P C Rensen; M C Jong; L C van Vark; H van der Boom; W L Hendriks; T J van Berkel; E A Biessen; L M Havekes
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

7.  Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.

Authors:  Jitske de Vries-van der Weij; Willeke de Haan; Lihui Hu; Maarten Kuif; H Ling D W Oei; José W A van der Hoorn; Louis M Havekes; Hans M G Princen; Johannes A Romijn; Johannes W A Smit; Patrick C N Rensen
Journal:  Endocrinology       Date:  2009-01-15       Impact factor: 4.736

8.  Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.

Authors:  Daniel Bloomfield; Gary L Carlson; Aditi Sapre; Diane Tribble; James M McKenney; Thomas W Littlejohn; Christine McCrary Sisk; Yale Mitchel; Richard C Pasternak
Journal:  Am Heart J       Date:  2008-12-20       Impact factor: 4.749

Review 9.  Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: studies using genetically engineered mouse models.

Authors:  Peter J Voshol; Patrick C N Rensen; Ko Willems van Dijk; Johannes A Romijn; Louis M Havekes
Journal:  Biochim Biophys Acta       Date:  2009-01-08

10.  Cholesteryl ester transfer protein (CETP) increases postprandial triglyceridaemia and delays triacylglycerol plasma clearance in transgenic mice.

Authors:  Alessandro G Salerno; Patrícia R Patrício; Jairo A Berti; Helena C F Oliveira
Journal:  Biochem J       Date:  2009-05-01       Impact factor: 3.857

View more
  4 in total

1.  Cholesteryl ester transfer protein alters liver and plasma triglyceride metabolism through two liver networks in female mice.

Authors:  Brian T Palmisano; Thao D Le; Lin Zhu; Yoon Kwang Lee; John M Stafford
Journal:  J Lipid Res       Date:  2016-06-27       Impact factor: 5.922

2.  Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1β-induced chronic inflammation.

Authors:  Wen Liang; Jan H Lindeman; Aswin L Menke; Debby P Koonen; Martine Morrison; Louis M Havekes; Anita M van den Hoek; Robert Kleemann
Journal:  Lab Invest       Date:  2014-02-24       Impact factor: 5.662

Review 3.  Hyperlipidaemia and cardioprotection: Animal models for translational studies.

Authors:  Ioanna Andreadou; Rainer Schulz; Lina Badimon; Adriana Adameová; Petra Kleinbongard; Sandrine Lecour; Panagiota-Efstathia Nikolaou; Ines Falcão-Pires; Gemma Vilahur; Nicholas Woudberg; Gerd Heusch; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

4.  Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice.

Authors:  Chunxiu Hu; Heng Wei; Anita M van den Hoek; Mei Wang; Rob van der Heijden; Gerwin Spijksma; Theo H Reijmers; Jildau Bouwman; Suzan Wopereis; Louis M Havekes; Elwin Verheij; Thomas Hankemeier; Guowang Xu; Jan van der Greef
Journal:  PLoS One       Date:  2011-05-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.